Case Study: Boston Scientific achieves greater support for innovative cancer care funding with PLMR Healthcomms

Boston Scientific launches Innovative Cancer Care Manifesto in Parliament with PLMR, backed by 367,000 annual cancer cases

The customer, Boston Scientific, faced the challenge that a new generation of highly effective cancer therapies, often involving medical devices, were not routinely funded by the NHS. These treatments did not fit existing funding mechanisms, including the Cancer Drugs Fund, limiting patient access. PLMR Healthcomms was engaged to lead a public affairs campaign to address this funding gap.

PLMR developed and launched the Innovative Cancer Care Fund Manifesto in Parliament in January 2020. The solution involved campaigning to extend NHS payment systems to cover these device-based therapies, successfully gaining support from numerous Parliamentarians for the cause.

Boston Scientific